Skip to main content

Table 2 Costs estimated for a three-month period (one Markov model cycle) of each health state of the model, in Brazilian real (BRL) and percentage (%) by category in strategy 2 (XELOX plus bevacizumab)

From: Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

Categories

First-line treatment (XELOX plus bevacizumab)

Second-line treatment (FOLFIRI)

Clinical Support

Death

R$

%

R$

%

R$

%

R$

%

Medications

27,592.00

89.57

4327.80

33.33

0.00

0.00

0.00

0.00

Preparation (Pharmacy)

120.08

0.39

270.18

2.08

0.00

0.00

0.00

0.00

Administration (Nursing)

1006.40

3.27

6700.74

51.61

0.00

0.00

0.00

0.00

Laboratory tests

367.00

1.19

409.08

3.15

265.48

5.28

0.00

0.00

Imaging tests

1720.00

5.58

1276.20

9.83

0.00

0.00

0.00

0.00

Hospitalization

0.00

0.00

0.00

0.00

4767.03

94.72

0.00

0.00

Total

30,805.48

100.00

12,984.00

100.00

5032.51

100.00

0.00

0.00

  1. Abbreviations: XELOX Xeloda® and oxaliplatin, FOLFIRI 5-fluorouracil, leucovorin and irinotecan